Litman Gregory Wealth Management LLC Buys 22,445 Shares of Zoetis Inc. $ZTS

Litman Gregory Wealth Management LLC increased its stake in Zoetis Inc. (NYSE:ZTS) by 289.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,207 shares of the company’s stock after purchasing an additional 22,445 shares during the period. Litman Gregory Wealth Management LLC’s holdings in Zoetis were worth $4,420,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Nova Wealth Management Inc. bought a new stake in shares of Zoetis during the first quarter worth $25,000. 1248 Management LLC acquired a new stake in Zoetis in the first quarter worth about $27,000. Saudi Central Bank bought a new stake in Zoetis during the 1st quarter worth about $29,000. REAP Financial Group LLC lifted its position in Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after purchasing an additional 131 shares during the period. Finally, NewSquare Capital LLC boosted its stake in shares of Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

Shares of ZTS stock opened at $126.16 on Friday. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.40. The firm has a fifty day moving average of $127.05 and a 200-day moving average of $143.14. The firm has a market capitalization of $55.60 billion, a price-to-earnings ratio of 21.24, a price-to-earnings-growth ratio of 2.73 and a beta of 0.97.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same period in the previous year, the company posted $1.58 earnings per share. The company’s revenue for the quarter was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be given a $0.53 dividend. The ex-dividend date is Tuesday, January 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. This is a boost from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s payout ratio is presently 33.67%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ZTS shares. Barclays assumed coverage on shares of Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target for the company. JPMorgan Chase & Co. lowered their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. KeyCorp started coverage on Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating on the stock. Argus restated a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Finally, Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Hold” and a consensus price target of $160.18.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.